相似文献
1
Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.
Nat Med. 2017 Aug 4;23(8):917-928. doi: 10.1038/nm.4381.
2
How genomics is contributing to the fight against artemisinin-resistant malaria parasites.
Acta Trop. 2015 Aug;148:1-7. doi: 10.1016/j.actatropica.2015.04.007. Epub 2015 Apr 21.
3
Plasmodium falciparum resistance to artemisinin-based combination therapies: A sword of Damocles in the path toward malaria elimination.
Parasite. 2018;25:24. doi: 10.1051/parasite/2018021. Epub 2018 Apr 20.
4
Induction of Multidrug Tolerance in Plasmodium falciparum by Extended Artemisinin Pressure.
Emerg Infect Dis. 2015 Oct;21(10):1733-41. doi: 10.3201/eid2110.150682.
5
Artemisinin-Resistant Plasmodium falciparum Malaria.
Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.EI10-0013-2016.
6
Triple Artemisinin-Based Combination Therapies for Malaria - A New Paradigm?
Trends Parasitol. 2021 Jan;37(1):15-24. doi: 10.1016/j.pt.2020.09.011. Epub 2020 Oct 12.
7
Artemisinin derivatives and malaria: useful, in combination with other antimalarials.
Prescrire Int. 2008 Aug;17(96):162-8.
8
Antimalarial drug resistance in Africa: the calm before the storm?
Lancet Infect Dis. 2019 Oct;19(10):e338-e351. doi: 10.1016/S1473-3099(19)30261-0. Epub 2019 Jul 30.
9
Artemisinin Action and Resistance in Plasmodium falciparum.
Trends Parasitol. 2016 Sep;32(9):682-696. doi: 10.1016/j.pt.2016.05.010. Epub 2016 Jun 9.
10
Artemisinin resistance in Plasmodium falciparum: what is it really?
Trends Parasitol. 2013 Jul;29(7):318-20. doi: 10.1016/j.pt.2013.05.002. Epub 2013 Jun 11.
引用本文的文献
1
Novel Inhibitors of Phosphatidylinositol 4-kinase IIIβ with Low Propensity for Resistance: Life Cycle Stage Activity and Efficacy in a Humanized Mouse Malaria Infection Model.
J Med Chem. 2025 Aug 28;68(16):17736-17751. doi: 10.1021/acs.jmedchem.5c01417. Epub 2025 Aug 14.
2
Antimalarial activity of root extract of Tephrosia villosa L. Pers. (Fabaceae) on Plasmodium berghei-infected mice.
Sci Rep. 2025 Jul 25;15(1):27162. doi: 10.1038/s41598-025-11137-0.
3
Direct long-read visualization reveals hidden variation in GCH1 gene copy number and precise expansion steps.
BMC Genomics. 2025 Jul 17;26(1):671. doi: 10.1186/s12864-025-11859-5.
4
Comprehensive genomic study of Plasmodium falciparum in Sierra leone: genetic variation and resistance patterns.
BMC Genomics. 2025 Jul 1;26(1):584. doi: 10.1186/s12864-025-11771-y.
5
Malaria: past, present, and future.
Signal Transduct Target Ther. 2025 Jun 17;10(1):188. doi: 10.1038/s41392-025-02246-3.
6
A comprehensive review of cerebral malaria.
J Parasit Dis. 2025 Jun;49(2):257-272. doi: 10.1007/s12639-024-01758-z. Epub 2024 Nov 15.
7
Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa.
Parasites Hosts Dis. 2025 May;63(2):109-122. doi: 10.3347/PHD.24053. Epub 2025 May 26.
8
Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus.
J Antimicrob Chemother. 2025 Jul 1;80(7):1972-1979. doi: 10.1093/jac/dkaf157.
9
The fast-evolving FIKK kinase family of Plasmodium falciparum can be inhibited by a single compound.
Nat Microbiol. 2025 May 19. doi: 10.1038/s41564-025-02017-4.
10
The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against Malaria.
Angew Chem Int Ed Engl. 2025 Jul 7;64(28):e202425206. doi: 10.1002/anie.202425206. Epub 2025 May 15.
本文引用的文献
1
Protein Degradation Systems as Antimalarial Therapeutic Targets.
Trends Parasitol. 2017 Sep;33(9):731-743. doi: 10.1016/j.pt.2017.05.009. Epub 2017 Jul 5.
2
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.
Nat Commun. 2017 May 24;8:15159. doi: 10.1038/ncomms15159.
3
A Variant PfCRT Isoform Can Contribute to Resistance to the First-Line Partner Drug Piperaquine.
mBio. 2017 May 9;8(3):e00303-17. doi: 10.1128/mBio.00303-17.
4
Oxidative stress in malaria and artemisinin combination therapy: Pros and Cons.
FEBS J. 2017 Aug;284(16):2579-2591. doi: 10.1111/febs.14097. Epub 2017 May 25.
5
Antimalarial efficacy of MMV390048, an inhibitor of phosphatidylinositol 4-kinase.
Sci Transl Med. 2017 Apr 26;9(387). doi: 10.1126/scitranslmed.aad9735.
6
K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness .
mBio. 2017 Apr 11;8(2):e00172-17. doi: 10.1128/mBio.00172-17.
7
Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis.
Sci Rep. 2017 Apr 6;7:45963. doi: 10.1038/srep45963.
8
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
Lancet Infect Dis. 2017 Jun;17(6):626-635. doi: 10.1016/S1473-3099(17)30171-8. Epub 2017 Mar 28.
9
Targeting the Parasite to Suppress Malaria Transmission.
Adv Parasitol. 2017;97:147-185. doi: 10.1016/bs.apar.2016.09.004. Epub 2016 Nov 12.
10
Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis.
Nat Microbiol. 2017 Mar 13;2:17031. doi: 10.1038/nmicrobiol.2017.31.
Zotero 插件